

PharmLabs San Diego Certificate of Analysis



Sample **PLUGPLAYHEMP-LIVEST-GUAVA GUSHERS**

Delta9 THC **ND** THCa **3.00%** Total THC (THC + THCa) **3.00%** Delta8 THC **56.66%**

Sample ID **SD240508-026 (94163)** Matrix **Concentrate (Inhalable Cannabis Good)**
 Tested for **A8 Industries**
 Sampled **-** Received **May 08, 2024** Reported **May 09, 2024**
 Analyses executed **CANX, QARUSH**

CANX - Cannabinoids Analysis

Analyzed **May 09, 2024** | Instrument **HPLC-VWD** | Method **SOP-001**
 The expanded Uncertainty of the Cannabinoid analysis is approximately **±.806%** at the 95% Confidence Level

| Analyte | LOD mg/g | LOQ mg/g | Result % | Result mg/g |
|---|----------|----------|--------------|---------------|
| 11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THCV) | 0.013 | 0.041 | ND | ND |
| Cannabidiol (CBD) | 0.002 | 0.007 | ND | ND |
| Abnormal Cannabidiol (a-CBD) | 0.01 | 0.031 | ND | ND |
| (+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC) | 0.012 | 0.036 | ND | ND |
| 11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC) | 0.007 | 0.021 | ND | ND |
| Cannabidiolic Acid (CBDA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol Acid (CBGA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol (CBG) | 0.001 | 0.16 | ND | ND |
| Cannabidiol (CBD) | 0.001 | 0.16 | ND | ND |
| 1(S)-THD (s-THD) | 0.013 | 0.041 | ND | ND |
| 1(R)-THD (r-THD) | 0.025 | 0.075 | ND | ND |
| Tetrahydrocannabinol (THCV) | 0.001 | 0.16 | <LOQ | <LOQ |
| Δ8-tetrahydrocannabinol (Δ8-THCV) | 0.021 | 0.064 | 0.21 | 2.10 |
| Cannabidiol (CBDH) | 0.005 | 0.16 | ND | ND |
| Tetrahydrocannabinol (Δ9-THCB) | 0.013 | 0.038 | ND | ND |
| Cannabinol (CBN) | 0.001 | 0.16 | 0.62 | 6.22 |
| Cannabidiophorol (CBDP) | 0.015 | 0.047 | ND | ND |
| exo-THC (exo-THC) | 0.005 | 0.16 | ND | ND |
| Tetrahydrocannabinol (Δ9-THC) | 0.003 | 0.16 | ND | ND |
| Δ8-tetrahydrocannabinol (Δ8-THC) | 0.004 | 0.16 | 56.66 | 566.65 |
| (6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10) | 0.015 | 0.16 | ND | ND |
| Hexahydrocannabinol (S Isomer) (9s-HHC) | 0.017 | 0.16 | 7.18 | 71.75 |
| (6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10) | 0.007 | 0.16 | ND | ND |
| Hexahydrocannabinol (R Isomer) (9r-HHC) | 0.016 | 0.16 | 12.42 | 124.24 |
| Tetrahydrocannabinolic Acid (THCA) | 0.001 | 0.16 | 3.42 | 34.25 |
| Δ9-Tetrahydrocannabinol (Δ9-THCH) | 0.024 | 0.071 | 3.30 | 32.99 |
| Cannabinol Acetate (CBNO) | 0.014 | 0.043 | ND | ND |
| Δ9-Tetrahydrocannabinol (Δ9-THCP) | 0.017 | 0.16 | 3.32 | 33.17 |
| Δ8-Tetrahydrocannabinol (Δ8-THCP) | 0.041 | 0.16 | ND | ND |
| Cannabicitran (CBT) | 0.005 | 0.16 | ND | ND |
| Δ8-THC-O-acetate (Δ8-THCO) | 0.076 | 0.16 | ND | ND |
| 9(S)-HHCP (s-HHCP) | 0.031 | 0.094 | ND | ND |
| Δ9-THC-O-acetate (Δ9-THCO) | 0.066 | 0.16 | ND | ND |
| 9(R)-HHCP (r-HHCP) | 0.026 | 0.079 | ND | ND |
| 9(S)-HHC-O-acetate (s-HHCO) | 0.005 | 0.16 | ND | ND |
| 9(R)-HHC-O-acetate (r-HHCO) | 0.008 | 0.025 | ND | ND |
| 3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8) | 0.067 | 0.204 | ND | ND |
| Total THC (THCa * 0.877 + Δ9THC) | | | 3.00 | 30.04 |
| Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC) | | | 59.67 | 596.69 |
| Total CBD (CBDA * 0.877 + CBD) | | | ND | ND |
| Total CBG (CBGA * 0.877 + CBG) | | | ND | ND |
| Total HHC (9r-HHC + 9s-HHC) | | | 19.60 | 195.99 |
| Total Cannabinoids Analyzed | | | 86.72 | 867.16 |

UJ Unidentified
 ND Not Detected
 N/A Not Applicable
 NT Not Reported
 LOD Limit of Detection
 LOQ Limit of Quantification
 <LOQ Detected
 >ULOL Above upper limit of linearity
 CFU/g Colony Forming Units per 1 gram
 TNTC Too Numerous to Count



DCC license: **C8-0000098-LIC**
 DEA license: **RP0611043**
 ISO/IEC 17025:2017 Acc. L17-427-1



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager
 Thu, 09 May 2024 14:33:52 -0700

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. L17-427-1



*This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evaluation unless explicitly required by federal, state or local laws and has been reported on the certificate of analysis. Measurement of uncertainty is available upon request.